DNLI Begins Rolling BLA Submission for Hunter Syndrome Drug, Stock UpZacks Investment Research • 04/03/25
Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START ProgramGlobeNewsWire • 04/02/25
Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business HighlightsGlobeNewsWire • 02/27/25
Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp AlfaGlobeNewsWire • 02/06/25
DNLI's Hunter Syndrome Drug Gets Breakthrough Therapy DesignationZacks Investment Research • 01/09/25
Denali Reverses Its Fortunes With 'Too Early' Miss In ALS TreatmentInvestors Business Daily • 01/07/25
Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform TrialGlobeNewsWire • 01/06/25
Why Is Denali Therapeutics (DNLI) Down 21.2% Since Last Earnings Report?Zacks Investment Research • 12/09/24
Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business HighlightsGlobeNewsWire • 11/06/24
Denali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseZacks Investment Research • 10/29/24
Strength Seen in Denali Therapeutics (DNLI): Can Its 10.1% Jump Turn into More Strength?Zacks Investment Research • 09/16/24